Brady Kelly reported option exercise involving 181 shares of Seres Therapeutics, Inc. on Aug 15, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
See Remarks
See Remarks
Filed Aug 18, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
181Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
8,743Direct
Trade date
Aug 15, 2026Option exercise
Filed
Aug 18, 2026, 5:33 PM ET3-day reporting delay
Accession
0001193125-26-355734Code M · Transaction 3344
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 15, 2026Option exercise90$0.00$0Trade 3346
Aug 15, 2026Option exercise91$0.00$0Trade 3347
Aug 17, 2026Sell64$4.55−$291.20Trade 3345
4 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

MCRB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
MCRB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +19%1w ago +12%1d ago +4.6%
Returns since7d +15%30d −5.8%90d180d1y

Footnotes in full

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 26, 2025, with the intent to cover taxes in connection with the vesting of the restricted stock units. F3: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date. F4: The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.